Fat Loss Peptides:
The Definitive Ranking
Every fat-loss peptide ranked by mechanism, speed, and lean-mass preservation. From GLP-1 agonists to GH-axis compounds — find the protocol that matches your goal.
How Fat Loss Peptides Actually Work
Fat loss peptides don't share a single mechanism — they hit four distinct biological pathways, each with a different risk/benefit profile and ideal use case. Understanding which pathway you're targeting is the foundation of any effective protocol.
GLP-1 / GIP Receptor Agonism
Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors sit in the hypothalamus, gut, and pancreas. Agonizing them slows gastric emptying, amplifies satiety signaling after meals, and sharply reduces appetite. Result: effortless caloric restriction without hunger — the dominant mechanism of semaglutide, tirzepatide, and retatrutide.
Growth Hormone Axis → Lipolysis
GH pulses activate hormone-sensitive lipase in fat cells, breaking stored triglycerides into free fatty acids for oxidation. GHRH analogues (CJC-1295) and GH secretagogues (ipamorelin, hexarelin) amplify natural GH pulses — especially the deep-sleep pulse — to drive overnight fat oxidation while sparing lean mass.
Melanocortin System
AOD-9604 engages beta-3 adrenergic receptors via a pathway adjacent to the melanocortin system, stimulating lipolysis directly in adipose tissue while simultaneously blocking lipogenesis. Unlike full GH, this fragment is fat-selective — no blood sugar, no IGF-1, no anabolic side effects. Pure fat mobilization.
Peptide-Driven Metabolic Rate (AMPK)
MOTS-c, encoded in mitochondrial DNA, activates AMPK — the master metabolic switch. AMPK activation mimics the cellular effects of fasting and exercise: increased fatty acid oxidation, improved insulin sensitivity, upregulated mitochondrial biogenesis, and preferential burning of visceral fat. The only peptide that improves metabolic rate at the cellular level.
Tier 1: GLP-1 / GIP Agonists
The most powerful fat loss compounds available in 2026. Clinical data shows 10–17.5% bodyweight reduction across 24 weeks — outcomes that exceed any prior pharmaceutical or lifestyle intervention.
GLP-1 Weekly Dosing Ramp (Semaglutide Example)
Weeks 1–4: 0.25mg weekly · Weeks 5–8: 0.5mg · Weeks 9–12: 1mg · Weeks 13+: 1.5–2.4mg based on tolerance. Ramp slowly to minimize GI side effects. Tirzepatide follows the same principle starting at 2.5mg and stepping to 5, 10, 15mg. Retatrutide Phase 2 doses ranged from 1–12mg weekly — start conservatively at 1–2mg.
Tier 2: GH-Axis Fat Loss Peptides
GH-axis peptides work more slowly than GLP-1s but preserve and build lean mass while promoting fat oxidation — making them ideal for recomposition rather than pure scale movement. They also carry none of the GI side effects associated with GLP-1 class compounds.
AOD-9604
The C-terminal fragment of HGH (residues 177–191) isolated purely for its lipolytic activity. AOD-9604 activates beta-3 adrenergic receptors to stimulate fat breakdown while simultaneously blocking new fat storage. Unlike full HGH, it causes zero blood sugar disruption and zero IGF-1 elevation. Administered at 250–500mcg subcutaneously in a fasted state each morning. Effects are fat-selective and most pronounced in stubborn subcutaneous depots.
Hexarelin
A potent GHRP-6 analogue that stimulates robust GH pulses without the hunger spike associated with GHRP-6. Hexarelin's GH stimulation is among the strongest of any secretagogue peptide, and the resulting GH elevation drives significant lipolysis over weeks of use. It also shows direct cardiac-protective activity via GHS receptor expression in myocardial tissue. Dose: 100–200mcg 2–3x daily, pre-workout or fasted.
CJC-1295 / Ipamorelin: Overnight Fat Oxidation
CJC-1295 (GHRH analogue) plus Ipamorelin (selective GHRP) is the most widely used GH-axis fat loss stack. CJC-1295 extends the amplitude of GH pulses; Ipamorelin enhances pulse frequency without raising cortisol or prolactin. Administered together pre-sleep (10 mins before bed, fasted for 2hrs), the stack capitalizes on the body's largest natural GH pulse during slow-wave sleep — driving fat oxidation through the night while sparing muscle.
Tier 3: Metabolic Optimization Support
These compounds don't generate dramatic scale movement on their own — but they address root causes of metabolic dysfunction that block fat loss and accelerate results when stacked with Tier 1 or 2 compounds.
MOTS-c
Encoded in mitochondrial DNA, MOTS-c is the only known peptide that functions as an "exercise mimetic." It activates AMPK, the master metabolic regulator, driving increased fatty acid oxidation, improved insulin sensitivity, and preferential reduction of visceral adipose tissue — the metabolically dangerous fat surrounding organs. MOTS-c levels decline with age and correlate with metabolic disease risk.
BPC-157
Body Protective Compound 157 is a gastric pentadecapeptide with documented gut barrier restoration activity. Leaky gut and microbiome disruption are increasingly recognized as drivers of metabolic dysfunction and obesity. BPC-157 repairs tight junction integrity, modulates gut motility, and reduces systemic inflammation — creating a metabolic environment more conducive to fat loss and insulin sensitivity. It is often stacked under GLP-1 protocols to reduce GI side effects.
Fat Loss Peptide Comparison Table
| Compound | Mechanism | Inject Freq | Avg Fat Loss | Lean Mass | Cost Tier | Best For |
|---|---|---|---|---|---|---|
| Semaglutide | GLP-1 agonist | 1x / week | 10–15% BW | Slight loss | $ | First GLP-1 cycle |
| Tirzepatide | GLP-1 + GIP dual | 1x / week | 15–22% BW | Better preserved | $$ | Max fat loss |
| Retatrutide | GLP-1+GIP+GCG triple | 1x / week | 17.5%+ BW | Energy expenditure↑ | $$$ | Fastest results |
| AOD-9604 | Beta-3 lipolysis | 1x / day | Moderate | Neutral / positive | $ | Stubborn fat, safety |
| CJC/Ipamorelin | GH axis / GHRH+GHRP | 1x / day | Gradual recomp | Builds muscle | $ | Recomp, anti-aging |
| MOTS-c | AMPK / mitochondrial | 3x / week | Visceral focus | Preserves | $$ | Metabolic health |
Protocol by Goal
Maximum Scale Movement — Tirzepatide or Retatrutide
For those whose primary goal is total body fat reduction, a GLP-1/GIP agonist is the most effective single compound. Start with tirzepatide at 2.5mg weekly, ramping by 2.5mg every 4 weeks to tolerance (up to 15mg). Pair with 150–200g protein daily and 2–3x/week resistance training to preserve lean mass. Add BPC-157 at 250mcg/day to manage GI side effects during ramp-up.
Simultaneous Fat Loss + Muscle Building — CJC-1295/Ipamorelin + AOD-9604
For those wanting to lose fat while improving muscle quality and aesthetics, combine GH-axis optimization with targeted lipolysis. CJC-1295 No-DAC (100–200mcg) + Ipamorelin (200–300mcg) pre-sleep for overnight GH pulse amplification. AOD-9604 (250–500mcg) fasted morning for direct fat mobilization. This stack produces slower scale movement than GLP-1s but superior aesthetic outcomes and no lean mass loss.
Root-Cause Metabolic Repair — MOTS-c + BPC-157
For those with insulin resistance, metabolic syndrome, or who want fat loss without appetite suppression or GI disruption, MOTS-c plus BPC-157 addresses the underlying metabolic dysfunction. MOTS-c (5–10mg/week, 3 injections) activates AMPK to restore cellular energy sensing and target visceral fat. BPC-157 (250–500mcg/day) repairs gut barrier integrity and reduces systemic inflammation. Amplify results by pairing with zone-2 cardio 3–4x/week — MOTS-c's effects are dramatically enhanced by concurrent exercise.
Results Timeline: What to Expect Week by Week
GLP-1 users notice the first meaningful reduction in appetite — meals feel satisfying with smaller portions. Cravings for high-calorie foods diminish. GH-axis users may notice improved sleep quality and subtle energy improvements. No visible body changes yet.
GLP-1 users: 2–5 lbs of weight loss typical, driven primarily by reduced caloric intake. AOD-9604 users begin noticing subtle reduction in the most stubborn fat areas. MOTS-c users: improved energy during exercise, early insulin sensitivity improvements measurable by fasting glucose.
Most significant visible changes occur in this window. GLP-1 users: 5–15 lbs lost depending on dose. Recomp stack users: noticeable improvements in muscle definition as fat recedes and muscle quality improves. Waistline and visceral fat reduction become apparent.
Full metabolic adaptation achieved. GLP-1 users reach maximum tolerated dose, fat loss rate stabilizes at 1–2 lbs/week. Body fat percentage at its lowest point of the cycle. Lean mass maintained or improved with proper protein intake and resistance training. Metabolic markers (fasting insulin, triglycerides, HbA1c) measurably improved.
Research-Grade Fat Loss Peptides
Semaglutide
GLP-1 receptor agonist — appetite suppression + insulin sensitivity
Tirzepatide
GLP-1 + GIP dual agonism — superior fat loss vs. semaglutide alone
Retatrutide
GLP-1 + GIP + glucagon triple agonism — fastest fat loss in clinical data
AOD-9604
Isolated HGH lipolytic fragment — no IGF-1, no blood sugar effects
MOTS-c
AMPK activation — exercise mimetic, visceral fat targeting
CJC-1295 + Ipamorelin
GHRH + GHRP synergy — overnight fat oxidation with muscle preservation
Frequently Asked Questions
What is the fastest fat loss peptide?
Retatrutide produces the fastest clinically documented fat loss — up to 17.5% bodyweight in 24 weeks via triple GLP-1/GIP/glucagon receptor agonism. For most users, tirzepatide offers the next-best combination of speed and tolerability, with 15–22% bodyweight loss over longer cycles.
Can I use peptides for fat loss without exercise?
GLP-1 agonists (semaglutide, tirzepatide, retatrutide) drive significant fat loss even without structured exercise via appetite suppression. However, exercise dramatically improves lean mass preservation. GH-axis peptides and MOTS-c have their fat loss effects amplified substantially by exercise and produce minimal results in fully sedentary use.
Will I regain weight when I stop fat loss peptides?
Yes — GLP-1 users typically regain ~65% of lost weight within one year of stopping, as the compounds suppress appetite pharmacologically rather than permanently resetting metabolism. Minimize regain by tapering doses slowly, building sustainable dietary habits during the active phase, and transitioning to a lower-dose maintenance protocol.
How do fat loss peptides compare to Ozempic?
Ozempic is the brand name for semaglutide — the same molecule available as research-grade semaglutide. Research peptides are functionally identical in mechanism but carry no FDA approval for human use. Tirzepatide (Mounjaro/Zepbound) and retatrutide represent next-generation compounds that outperform Ozempic in clinical fat loss data.
Do fat loss peptides preserve muscle?
GLP-1s alone cause some lean mass loss (25–40% of total weight lost). Pairing with resistance training and 1.6–2g/kg protein reduces this significantly. GH-axis peptides (CJC-1295/Ipamorelin) actively preserve and build lean mass. AOD-9604 is fat-selective with neutral lean mass effects. The best recomp combination is a low-dose GLP-1 paired with CJC-1295/Ipamorelin.
